256 related articles for article (PubMed ID: 29930762)
1. Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer.
Nakamichi S; Seike M; Miyanaga A; Chiba M; Zou F; Takahashi A; Ishikawa A; Kunugi S; Noro R; Kubota K; Gemma A
Oncotarget; 2018 Jun; 9(43):27242-27255. PubMed ID: 29930762
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation.
Kim HR; Kim WS; Choi YJ; Choi CM; Rho JK; Lee JC
Mol Oncol; 2013 Dec; 7(6):1093-102. PubMed ID: 23993685
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
4. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.
Debruyne DN; Bhatnagar N; Sharma B; Luther W; Moore NF; Cheung NK; Gray NS; George RE
Oncogene; 2016 Jul; 35(28):3681-91. PubMed ID: 26616860
[TBL] [Abstract][Full Text] [Related]
5. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
6. ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells.
Gao Y; Liu T; Liu J; Yang Y; Sun K; Li Z; Zhai X; Zuo D
Chem Biol Interact; 2023 Jul; 379():110516. PubMed ID: 37116853
[TBL] [Abstract][Full Text] [Related]
7. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
Katayama R; Friboulet L; Koike S; Lockerman EL; Khan TM; Gainor JF; Iafrate AJ; Takeuchi K; Taiji M; Okuno Y; Fujita N; Engelman JA; Shaw AT
Clin Cancer Res; 2014 Nov; 20(22):5686-96. PubMed ID: 25228534
[TBL] [Abstract][Full Text] [Related]
8. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
9. Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.
Miyawaki M; Yasuda H; Tani T; Hamamoto J; Arai D; Ishioka K; Ohgino K; Nukaga S; Hirano T; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K
Mol Cancer Res; 2017 Jan; 15(1):106-114. PubMed ID: 27707887
[TBL] [Abstract][Full Text] [Related]
10. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of
Urbanska EM; Sørensen JB; Melchior LC; Costa JC; Santoni-Rugiu E
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325863
[No Abstract] [Full Text] [Related]
11. EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer.
Gower A; Hsu WH; Hsu ST; Wang Y; Giaccone G
Mol Oncol; 2016 Apr; 10(4):601-9. PubMed ID: 26639656
[TBL] [Abstract][Full Text] [Related]
12. [Effect and mechanism of silibinin on the inhibition of ALK positive NSCLC cells by sensitizing crizotinib].
Lin CC; Lu CH; Pan YH; Jiao L; Chen HY; Li L; He Y
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):650-656. PubMed ID: 28926892
[No Abstract] [Full Text] [Related]
13. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA
Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041
[TBL] [Abstract][Full Text] [Related]
14. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S; Zimmermann S
Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
[TBL] [Abstract][Full Text] [Related]
15. Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.
Arai S; Takeuchi S; Fukuda K; Taniguchi H; Nishiyama A; Tanimoto A; Satouchi M; Yamashita K; Ohtsubo K; Nanjo S; Kumagai T; Katayama R; Nishio M; Zheng MM; Wu YL; Nishihara H; Yamamoto T; Nakada M; Yano S
J Thorac Oncol; 2020 May; 15(5):752-765. PubMed ID: 31972351
[TBL] [Abstract][Full Text] [Related]
16. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
Yamaguchi N; Lucena-Araujo AR; Nakayama S; de Figueiredo-Pontes LL; Gonzalez DA; Yasuda H; Kobayashi S; Costa DB
Lung Cancer; 2014 Jan; 83(1):37-43. PubMed ID: 24199682
[TBL] [Abstract][Full Text] [Related]
17. AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.
Yang YM; Jang Y; Lee SH; Kang B; Lim SM
Lung Cancer; 2020 Aug; 146():70-77. PubMed ID: 32521387
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.
Sakashita T; Yanagitani N; Koike S; Low SK; Takagi S; Baba S; Takeuchi K; Nishio M; Fujita N; Katayama R
Cancer Sci; 2022 Nov; 113(11):3888-3900. PubMed ID: 35950895
[TBL] [Abstract][Full Text] [Related]
19. FAT4 activation inhibits epithelial-mesenchymal transition (EMT) by promoting autophagy in H2228/Cer cells.
Yang Y; Li Y; Yang Q; Liu Z; Chang X; Yang H; Liu J; Li Z; Zuo D
Med Oncol; 2022 Dec; 40(1):64. PubMed ID: 36576661
[TBL] [Abstract][Full Text] [Related]
20. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
Isozaki H; Ichihara E; Takigawa N; Ohashi K; Ochi N; Yasugi M; Ninomiya T; Yamane H; Hotta K; Sakai K; Matsumoto K; Hosokawa S; Bessho A; Sendo T; Tanimoto M; Kiura K
Cancer Res; 2016 Mar; 76(6):1506-16. PubMed ID: 26719536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
